Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
GSK starts phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
GSK today announced the start of a phase III study investigating Benlysta (belimumab) in combination with rituximab in adult patients with systemic lupus erythematosus (SLE).
Read more -
GSK announces positive EU approval for labelling update to Relvar Ellipta in patients with asthma
GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has approved a label update for the use of once-daily Relvar El...
Read more -
New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age
New data published in The Lancet Child & Adolescent Health from a Phase III clinical trial with Fluarix Tetra which prevented influenza A and B in children six to 35 months of age
Read more -
ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis
INSPIRING study results contribute to extensive body of evidence for dolutegravir
Read more -
Nucala (mepolizumab) improved asthma control in patients uncontrolled on Xolair (omalizumab)
Positive clinical study outcomes observed for severe eosinophilic asthma patients uncontrolled on omalizumab when switched to mepolizumab in an open-label single arm study
Read more -
GSK receives European approval for expanded indication for Fluarix Tetra (Influenza Vaccine) for ages six months and older
GSK announced the expanded indication for Fluarix Tetra has been approved in Europe.
Read more -
GSK submits landmark IMPACT data to European Medicines Agency to support expanded label for Trelegy Ellipta
GlaxoSmithKline plc and Innoviva, Inc. announce submission of landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label f...
Read more -
ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment
Today ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the start of a phase III study d...
Read more -
ViiV Healthcare files patent infringement litigation against Gilead Sciences Inc. over bictegravir
ViiV Healthcare announces it has filed patent infringement litigation against Gilead Sciences Inc. over bictegravir in the United States and Canada.
Read more -
GSK delivers improvements in sales, margins and cash flow in 2017
Total EPS 31.4p, +67% AER, +36% CER; Adjusted EPS 111.8p, +11% AER, +4% CER
Read more -
GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age
GlaxoSmithKline plc announced that it has received Breakthrough Therapy Designation from the U.S. FDA for its meningitis B vaccine Bexsero
Read more -
GSK’s Shingrix receives positive opinion from the CHMP in Europe for the prevention of shingles in adults aged 50 and over
Shingrix is a non-live, recombinant subunit adjuvanted vaccine given intramuscularly in two doses, with a two-to-six month interval between doses.
Read more -
GSK announces CHMP positive opinion for labelling update to Relvar Ellipta in patients with asthma
A positive CHMP opinion is one of the final steps before marketing authorisation is updated by the European Commission.
Read more -
GSK responds to the AMR Benchmark
The new AMR Benchmark provides a useful analysis of the industry’s contribution to addressing the severe public health threat of antimicrobial resistance
Read more -
FDA approves US label update on ICS/LABA combinations in asthma, based on review of safety data
Boxed warning removed from ICS/LABA combination products, including BREO ELLIPTA, ADVAIR DISKUS and ADVAIR HFA.
Read more -
GSK submits regulatory application for single-dose tafenoquine for the treatment of Plasmodium vivax malaria to Australia’s Therapeutic Goods Administration
Innovative science drives progress in developing medicines for infectious diseases.
Read more -
GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US
First targeted treatment approved for this rare eosinophil-driven disease
Read more -
GSK presents promising new data for priority BCMA asset from its emerging Oncology pipeline at 59th ASH meeting
Data from dose expansion phase of DREAMM-1 study
Read more -
New data supports the safety and efficacy of GSK’s Shingrix in preventing shingles in autologous haematopoietic stem cell transplant patients
New data supports the safety and efficacy of GSK’s Shingrix in preventing shingles in autologous haematopoietic stem cell transplant patients
Read more -
GSK welcomes launch of the UK Government’s Life Sciences Sector Deal
New £40 million GSK investment in genomic research
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
